Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
Status:
Suspended
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well pevonedistat alone or in combination with chemotherapy
(paclitaxel and carboplatin) works in treating patients with bile duct cancer of the liver.
Pevonedistat may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth. Chemotherapy drugs, such as paclitaxel and carboplatin, work in different ways
to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. This study may help the study doctors find out
how well pevonedistat shrinks bile duct cancer of the liver when given alone and when in
combination with paclitaxel and carboplatin.